MDCT-findings in patients with non-occlusive mesenteric ischemia (NOMI): influence of vasoconstrictor agents - Takeaways - MDSpire

MDCT-findings in patients with non-occlusive mesenteric ischemia (NOMI): influence of vasoconstrictor agents

  • By

  • Antoine Topolsky

  • Olivier Pantet

  • Lucas Liaudet

  • Christine Sempoux

  • Alban Denys

  • Jean-François Knebel

  • Sabine Schmidt

  • January 24, 2023

  • 0 min

Share

  • 1

    Non-occlusive mesenteric ischemia (NOMI) accounts for 20–30% of acute bowel ischemia cases and has a mortality rate of 70–90%.

  • 2

    Diagnosis of NOMI is challenging due to non-specific clinical signs and the need for advanced imaging techniques like MDCT.

  • 3

    Vasoconstrictor agents (VCAs) used in hemodynamically unstable patients may increase the risk of NOMI and influence MDCT findings.

  • 4

    MDCT is preferred over digital subtraction angiography for initial NOMI assessment due to its excellent spatial resolution and ability to show bowel signs.

  • 5

    The study involved 90 patients with confirmed NOMI, highlighting the importance of accurate imaging and timely intervention in critical care settings.

Original Source(s)

MDCT-findings in patients with non-occlusive mesenteric ischemia (NOMI): influence of vasoconstrictor agents

  • by Antoine Topolsky, Olivier Pantet, Lucas Liaudet, Christine Sempoux, Alban Denys, Jean-François Knebel, Sabine Schmidt

  • January 24, 2023

Related Content

Evaluation of large language models for diagnostic impression generation from brain MRI report findings: a multicenter benchmark and reader study

Multimodal deep learning with anatomically constrained attention for screening MRI-detectable TMJ abnormalities from panoramic images

FDA Clears AI Guidance Tool for Mitral Repair

AI enhances real-time intraprocedural visualization and navigation.